alogliptin and metformin hydrochloride
alogliptin and metformin hydrochloride is listed in the FDA National Drug Code directory with 9 NDC codes, marketed under brand names including alogliptin and metformin hydrochloride, KAZANO. Available dosage form: tablet, film coated.
Drug Details
- Generic Name
- alogliptin and metformin hydrochloride
- Brand Names
- alogliptin and metformin hydrochloride, KAZANO
- Application Number
- NDA203414
- Sponsor
- Takeda GmbH
- NDC Codes
- 9
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- ALOGLIPTIN BENZOATE, METFORMIN HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE Alogliptin and metformin HCl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin and metformin HCl tablets are a combination of alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor and metformin, a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin and metformin HCl tablets should not be used in patients with type 1 diabetes mellitus.